Core Insights - BioCardia, Inc. announced that the results of its CardiAMP HF Phase 3 study will be presented at the American College of Cardiology 2025 Scientific Sessions [1] - The CardiAMP autologous cell therapy has received FDA Breakthrough designation and aims to treat microvascular dysfunction through a minimally invasive procedure [3] Group 1: Study Presentation - The CardiAMP HF Phase 3 study results will be presented by Dr. Amish N. Raval on March 30, 2025, during a late-breaking clinical trials session [2] - The American College of Cardiology Scientific Sessions is a prominent forum for cardiovascular clinical trials, attracting experts from various related fields [2] Group 2: CardiAMP Cell Therapy - CardiAMP Cell Therapy utilizes a patient's own marrow cells to potentially enhance the body's natural healing response, targeting mechanisms of microvascular dysfunction [3] - The therapy aims to increase capillary density, reduce tissue fibrosis, and counteract fibrotic, inflammatory, apoptotic, and endothelial dysfunction through the production of growth factors and cytokines [3] Group 3: Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with multiple clinical stage product candidates [5] - The company’s therapies are supported by the Maryland Stem Cell Research Fund and are reimbursed by the Centers for Medicare and Medicaid Services [4]
BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions